| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Lymphocytic, Chronic, B-Cell | 185 | 2024 | 2486 | 16.790 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 111 | 2024 | 16689 | 2.720 |
Why?
|
| Rituximab | 55 | 2024 | 1594 | 2.690 |
Why?
|
| Pyrazoles | 28 | 2024 | 1546 | 2.100 |
Why?
|
| Pyrimidines | 47 | 2024 | 3669 | 1.990 |
Why?
|
| Adenine | 30 | 2024 | 674 | 1.760 |
Why?
|
| Thalidomide | 11 | 2016 | 597 | 1.760 |
Why?
|
| Vidarabine | 35 | 2021 | 1384 | 1.570 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 31 | 2023 | 2635 | 1.550 |
Why?
|
| Aged | 230 | 2024 | 73333 | 1.520 |
Why?
|
| Antineoplastic Agents | 66 | 2024 | 14617 | 1.510 |
Why?
|
| Piperidines | 29 | 2024 | 1100 | 1.470 |
Why?
|
| Aged, 80 and over | 122 | 2024 | 30998 | 1.280 |
Why?
|
| Cytarabine | 30 | 2023 | 2014 | 1.250 |
Why?
|
| Antibodies, Monoclonal | 38 | 2018 | 4481 | 1.250 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 30 | 2014 | 878 | 1.240 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 16 | 2024 | 1013 | 1.210 |
Why?
|
| Middle Aged | 226 | 2024 | 90352 | 1.190 |
Why?
|
| Humans | 341 | 2024 | 270740 | 1.170 |
Why?
|
| Protein Kinase Inhibitors | 30 | 2023 | 4961 | 1.170 |
Why?
|
| STAT3 Transcription Factor | 17 | 2022 | 1136 | 1.160 |
Why?
|
| Treatment Outcome | 116 | 2024 | 33737 | 1.070 |
Why?
|
| Cyclophosphamide | 37 | 2024 | 3245 | 1.040 |
Why?
|
| Adult | 179 | 2024 | 82040 | 1.030 |
Why?
|
| Remission Induction | 48 | 2023 | 3656 | 1.020 |
Why?
|
| Leukemia, Myeloid, Acute | 35 | 2023 | 7265 | 1.020 |
Why?
|
| Male | 224 | 2024 | 128315 | 1.010 |
Why?
|
| Neoplasms, Second Primary | 10 | 2021 | 1388 | 0.990 |
Why?
|
| Antibodies, Neoplasm | 14 | 2011 | 273 | 0.980 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 22 | 2022 | 2903 | 0.970 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 11 | 2023 | 531 | 0.950 |
Why?
|
| Female | 219 | 2024 | 148940 | 0.910 |
Why?
|
| Immunoglobulin Heavy Chains | 11 | 2024 | 244 | 0.900 |
Why?
|
| Sulfonamides | 17 | 2024 | 1933 | 0.890 |
Why?
|
| Prognosis | 68 | 2024 | 22505 | 0.870 |
Why?
|
| Cladribine | 10 | 2024 | 253 | 0.870 |
Why?
|
| Disease-Free Survival | 47 | 2021 | 10265 | 0.860 |
Why?
|
| Neoplasm, Residual | 24 | 2024 | 1754 | 0.850 |
Why?
|
| Trisomy | 4 | 2018 | 240 | 0.840 |
Why?
|
| Lymphocytosis | 5 | 2021 | 57 | 0.820 |
Why?
|
| Salvage Therapy | 18 | 2021 | 2123 | 0.810 |
Why?
|
| Immunologic Factors | 9 | 2019 | 672 | 0.800 |
Why?
|
| Recurrence | 35 | 2022 | 4878 | 0.780 |
Why?
|
| Drug Administration Schedule | 33 | 2020 | 3530 | 0.780 |
Why?
|
| Thrombocytopenia | 10 | 2022 | 870 | 0.780 |
Why?
|
| Virus Activation | 3 | 2021 | 237 | 0.770 |
Why?
|
| Leukemia, Promyelocytic, Acute | 9 | 2021 | 441 | 0.760 |
Why?
|
| Chromosomes, Human, Pair 12 | 4 | 2018 | 198 | 0.760 |
Why?
|
| Cytomegalovirus | 3 | 2018 | 496 | 0.750 |
Why?
|
| Myelodysplastic Syndromes | 23 | 2021 | 3156 | 0.750 |
Why?
|
| Biomarkers, Tumor | 25 | 2021 | 10708 | 0.740 |
Why?
|
| Kaplan-Meier Estimate | 30 | 2024 | 6256 | 0.720 |
Why?
|
| Autoimmune Diseases | 2 | 2022 | 436 | 0.720 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 9 | 2023 | 1739 | 0.720 |
Why?
|
| Antibodies, Monoclonal, Humanized | 27 | 2021 | 3409 | 0.710 |
Why?
|
| Immunophenotyping | 6 | 2023 | 1726 | 0.700 |
Why?
|
| Heart Diseases | 2 | 2023 | 724 | 0.700 |
Why?
|
| Dasatinib | 10 | 2022 | 881 | 0.690 |
Why?
|
| B-Lymphocytes | 9 | 2023 | 1424 | 0.690 |
Why?
|
| Consolidation Chemotherapy | 5 | 2020 | 153 | 0.680 |
Why?
|
| Receptors, Antigen, B-Cell | 6 | 2018 | 174 | 0.660 |
Why?
|
| Leukemia, Myeloid | 12 | 2007 | 993 | 0.660 |
Why?
|
| Chlorambucil | 1 | 2019 | 26 | 0.650 |
Why?
|
| MicroRNAs | 7 | 2018 | 2887 | 0.640 |
Why?
|
| Follow-Up Studies | 51 | 2024 | 15218 | 0.620 |
Why?
|
| Drug Resistance, Neoplasm | 19 | 2023 | 5408 | 0.620 |
Why?
|
| Anemia, Hemolytic | 1 | 2018 | 53 | 0.610 |
Why?
|
| Fusion Proteins, bcr-abl | 11 | 2020 | 1144 | 0.600 |
Why?
|
| Arabinonucleosides | 10 | 2024 | 470 | 0.580 |
Why?
|
| Chromosome Deletion | 10 | 2021 | 1049 | 0.580 |
Why?
|
| Vincristine | 16 | 2024 | 1583 | 0.580 |
Why?
|
| Immunoglobulin Variable Region | 6 | 2024 | 172 | 0.570 |
Why?
|
| beta 2-Microglobulin | 9 | 2015 | 189 | 0.550 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 8 | 2014 | 425 | 0.550 |
Why?
|
| Hypertension | 2 | 2023 | 1591 | 0.540 |
Why?
|
| Leukemia, Hairy Cell | 6 | 2024 | 129 | 0.540 |
Why?
|
| Philadelphia Chromosome | 9 | 2022 | 852 | 0.540 |
Why?
|
| Immunotherapy | 11 | 2019 | 3557 | 0.530 |
Why?
|
| Hydrazines | 5 | 2019 | 213 | 0.520 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 6 | 2024 | 107 | 0.520 |
Why?
|
| Survival Rate | 37 | 2024 | 12541 | 0.520 |
Why?
|
| Virus Diseases | 2 | 2017 | 393 | 0.510 |
Why?
|
| Retreatment | 3 | 2020 | 448 | 0.500 |
Why?
|
| Azacitidine | 10 | 2022 | 1218 | 0.500 |
Why?
|
| Chromosomes, Human, Pair 11 | 4 | 2015 | 413 | 0.480 |
Why?
|
| Bacterial Infections | 2 | 2016 | 510 | 0.480 |
Why?
|
| Asparaginase | 6 | 2024 | 196 | 0.480 |
Why?
|
| von Willebrand Diseases | 1 | 2015 | 55 | 0.480 |
Why?
|
| Chromosomes, Human, Pair 17 | 9 | 2021 | 668 | 0.460 |
Why?
|
| Bone Marrow | 11 | 2018 | 2441 | 0.460 |
Why?
|
| Dexamethasone | 14 | 2024 | 1516 | 0.460 |
Why?
|
| Alkylating Agents | 3 | 2010 | 81 | 0.460 |
Why?
|
| Idarubicin | 8 | 2023 | 459 | 0.460 |
Why?
|
| Neoplasm Proteins | 7 | 2019 | 3345 | 0.460 |
Why?
|
| Piperazines | 16 | 2013 | 2145 | 0.460 |
Why?
|
| Gene Expression Regulation, Leukemic | 7 | 2013 | 586 | 0.450 |
Why?
|
| Protein-Tyrosine Kinases | 15 | 2023 | 1838 | 0.450 |
Why?
|
| Benzoates | 3 | 2019 | 128 | 0.440 |
Why?
|
| Adenine Nucleotides | 8 | 2015 | 365 | 0.440 |
Why?
|
| Hematinics | 2 | 2013 | 108 | 0.440 |
Why?
|
| Mutation | 22 | 2022 | 15912 | 0.430 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2024 | 1067 | 0.430 |
Why?
|
| Antineoplastic Agents, Immunological | 6 | 2021 | 1335 | 0.410 |
Why?
|
| Arsenicals | 7 | 2021 | 205 | 0.410 |
Why?
|
| Leukemia, Prolymphocytic | 5 | 2019 | 54 | 0.410 |
Why?
|
| Viral Proteins | 1 | 2015 | 491 | 0.410 |
Why?
|
| Survival Analysis | 26 | 2019 | 9292 | 0.410 |
Why?
|
| Dose-Response Relationship, Drug | 21 | 2019 | 5056 | 0.400 |
Why?
|
| Hemorrhage | 2 | 2023 | 727 | 0.400 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2021 | 2453 | 0.400 |
Why?
|
| Hematologic Neoplasms | 6 | 2018 | 1956 | 0.400 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2022 | 10400 | 0.400 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 466 | 0.390 |
Why?
|
| CD40 Antigens | 1 | 2012 | 106 | 0.390 |
Why?
|
| Precision Medicine | 1 | 2019 | 1207 | 0.380 |
Why?
|
| Alemtuzumab | 14 | 2011 | 213 | 0.380 |
Why?
|
| Disease Progression | 25 | 2022 | 6867 | 0.380 |
Why?
|
| Imatinib Mesylate | 20 | 2019 | 1691 | 0.380 |
Why?
|
| Polyethylene Glycols | 5 | 2024 | 654 | 0.370 |
Why?
|
| Janus Kinase 2 | 5 | 2014 | 754 | 0.370 |
Why?
|
| Herpesvirus 4, Human | 2 | 2015 | 961 | 0.370 |
Why?
|
| Anemia | 4 | 2016 | 728 | 0.370 |
Why?
|
| Young Adult | 40 | 2024 | 22251 | 0.370 |
Why?
|
| Apoptosis | 14 | 2021 | 7757 | 0.360 |
Why?
|
| Health Status Disparities | 1 | 2013 | 318 | 0.350 |
Why?
|
| Antigens, CD | 10 | 2011 | 1418 | 0.350 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 2224 | 0.350 |
Why?
|
| In Situ Hybridization, Fluorescence | 7 | 2021 | 2313 | 0.340 |
Why?
|
| Evidence-Based Medicine | 3 | 2018 | 1034 | 0.330 |
Why?
|
| Flow Cytometry | 12 | 2019 | 3045 | 0.330 |
Why?
|
| Enzyme Inhibitors | 8 | 2019 | 1942 | 0.330 |
Why?
|
| Chromosome Aberrations | 10 | 2018 | 2035 | 0.330 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2010 | 191 | 0.320 |
Why?
|
| Lymphoma, B-Cell | 4 | 2022 | 929 | 0.320 |
Why?
|
| Positron-Emission Tomography | 2 | 2016 | 2197 | 0.320 |
Why?
|
| Interferon-alpha | 10 | 2007 | 959 | 0.310 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2019 | 2359 | 0.310 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2022 | 3658 | 0.310 |
Why?
|
| Signal Transduction | 13 | 2019 | 12103 | 0.310 |
Why?
|
| Cancer Survivors | 1 | 2016 | 742 | 0.310 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 2 | 2019 | 48 | 0.310 |
Why?
|
| Comorbidity | 4 | 2024 | 2394 | 0.300 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 1260 | 0.300 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2024 | 331 | 0.300 |
Why?
|
| Antibodies, Bispecific | 2 | 2022 | 282 | 0.290 |
Why?
|
| Tyrphostins | 1 | 2007 | 110 | 0.290 |
Why?
|
| SEER Program | 3 | 2024 | 1047 | 0.290 |
Why?
|
| Leukemia | 6 | 2010 | 1719 | 0.280 |
Why?
|
| Stem Cell Transplantation | 7 | 2022 | 1418 | 0.280 |
Why?
|
| Retrospective Studies | 35 | 2024 | 39890 | 0.280 |
Why?
|
| Lymphocyte Count | 6 | 2019 | 485 | 0.280 |
Why?
|
| Benzamides | 19 | 2023 | 1879 | 0.280 |
Why?
|
| Janus Kinases | 2 | 2012 | 175 | 0.280 |
Why?
|
| Oxides | 7 | 2021 | 212 | 0.280 |
Why?
|
| Lymphoma, Follicular | 3 | 2023 | 636 | 0.270 |
Why?
|
| STAT Transcription Factors | 1 | 2006 | 80 | 0.270 |
Why?
|
| Atrial Fibrillation | 3 | 2022 | 730 | 0.270 |
Why?
|
| Antigens, CD20 | 5 | 2018 | 207 | 0.270 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2018 | 155 | 0.270 |
Why?
|
| Proportional Hazards Models | 17 | 2024 | 5101 | 0.270 |
Why?
|
| Risk Factors | 21 | 2020 | 17888 | 0.260 |
Why?
|
| Pyridines | 3 | 2007 | 1313 | 0.260 |
Why?
|
| Adolescent | 38 | 2024 | 32767 | 0.260 |
Why?
|
| Melanoma | 1 | 2023 | 5595 | 0.260 |
Why?
|
| Neoplasm Staging | 16 | 2020 | 14012 | 0.260 |
Why?
|
| Bendamustine Hydrochloride | 4 | 2017 | 123 | 0.260 |
Why?
|
| Doxorubicin | 12 | 2024 | 3145 | 0.260 |
Why?
|
| Time Factors | 16 | 2019 | 13006 | 0.260 |
Why?
|
| Multivariate Analysis | 8 | 2019 | 4328 | 0.260 |
Why?
|
| Pancytopenia | 2 | 2018 | 119 | 0.250 |
Why?
|
| Withholding Treatment | 3 | 2016 | 155 | 0.250 |
Why?
|
| RNA, Viral | 3 | 2020 | 730 | 0.250 |
Why?
|
| Antigens, Neoplasm | 8 | 2010 | 1580 | 0.250 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2005 | 74 | 0.250 |
Why?
|
| Infectious Mononucleosis | 1 | 2005 | 38 | 0.250 |
Why?
|
| CD5 Antigens | 2 | 2017 | 130 | 0.250 |
Why?
|
| Interleukin-4 | 3 | 1994 | 290 | 0.250 |
Why?
|
| Tumor Cells, Cultured | 8 | 2021 | 5759 | 0.240 |
Why?
|
| Leukemia, B-Cell | 2 | 2017 | 114 | 0.240 |
Why?
|
| Pyrazines | 5 | 2023 | 510 | 0.240 |
Why?
|
| Splenectomy | 1 | 2005 | 168 | 0.230 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2002 | 1584 | 0.230 |
Why?
|
| Caspase 3 | 4 | 2016 | 474 | 0.230 |
Why?
|
| ADP-ribosyl Cyclase 1 | 5 | 2015 | 149 | 0.230 |
Why?
|
| Prednisone | 4 | 2017 | 1034 | 0.230 |
Why?
|
| Combined Modality Therapy | 12 | 2021 | 9039 | 0.220 |
Why?
|
| Neutropenia | 7 | 2019 | 1006 | 0.220 |
Why?
|
| Tretinoin | 7 | 2021 | 617 | 0.220 |
Why?
|
| Primary Myelofibrosis | 4 | 2019 | 914 | 0.220 |
Why?
|
| Cytogenetic Analysis | 5 | 2019 | 574 | 0.220 |
Why?
|
| Leukemia, T-Cell | 3 | 2009 | 90 | 0.220 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 4 | 2017 | 121 | 0.220 |
Why?
|
| Translocation, Genetic | 4 | 2021 | 1286 | 0.220 |
Why?
|
| Risk Assessment | 10 | 2021 | 6764 | 0.220 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2021 | 1269 | 0.210 |
Why?
|
| Immunoglobulin M | 3 | 2018 | 359 | 0.210 |
Why?
|
| Proteins | 3 | 2021 | 2043 | 0.210 |
Why?
|
| Australia | 1 | 2023 | 259 | 0.210 |
Why?
|
| Immunosuppressive Agents | 5 | 2018 | 1432 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2021 | 9042 | 0.210 |
Why?
|
| Pilot Projects | 9 | 2023 | 2828 | 0.210 |
Why?
|
| Acute Disease | 15 | 2010 | 2493 | 0.210 |
Why?
|
| Cell Proliferation | 10 | 2021 | 7238 | 0.210 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 9 | 2013 | 3597 | 0.200 |
Why?
|
| Cytokines | 5 | 2017 | 2825 | 0.200 |
Why?
|
| Chromosomes, Human | 3 | 2017 | 288 | 0.200 |
Why?
|
| Daunorubicin | 3 | 2020 | 314 | 0.200 |
Why?
|
| Serum Amyloid P-Component | 1 | 2022 | 31 | 0.200 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 9 | 2022 | 7044 | 0.200 |
Why?
|
| Chemokine CCL4 | 3 | 2016 | 68 | 0.200 |
Why?
|
| Chemokine CCL3 | 3 | 2016 | 65 | 0.200 |
Why?
|
| Immunization, Passive | 2 | 2018 | 188 | 0.200 |
Why?
|
| Poly(ADP-ribose) Polymerases | 3 | 2016 | 322 | 0.200 |
Why?
|
| Colony-Forming Units Assay | 5 | 2007 | 253 | 0.190 |
Why?
|
| Prospective Studies | 11 | 2023 | 13414 | 0.190 |
Why?
|
| Maintenance Chemotherapy | 2 | 2021 | 226 | 0.190 |
Why?
|
| Antimetabolites, Antineoplastic | 5 | 2019 | 1347 | 0.190 |
Why?
|
| Biomarkers | 5 | 2020 | 5051 | 0.190 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 4 | 2021 | 838 | 0.190 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2023 | 1051 | 0.190 |
Why?
|
| Infusions, Intravenous | 10 | 2013 | 1437 | 0.190 |
Why?
|
| Chemokine CXCL13 | 1 | 2020 | 20 | 0.180 |
Why?
|
| Tumor Microenvironment | 4 | 2022 | 3035 | 0.180 |
Why?
|
| Nausea | 5 | 2015 | 539 | 0.180 |
Why?
|
| Receptors, Growth Factor | 1 | 2001 | 157 | 0.180 |
Why?
|
| Neovascularization, Pathologic | 2 | 2011 | 1586 | 0.180 |
Why?
|
| Hematopoietic Stem Cells | 4 | 1994 | 1367 | 0.180 |
Why?
|
| Antibodies, Viral | 2 | 2017 | 1301 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 8 | 2016 | 3476 | 0.170 |
Why?
|
| Hepatitis C Antibodies | 1 | 2020 | 49 | 0.170 |
Why?
|
| Clinical Trials as Topic | 6 | 2020 | 3844 | 0.170 |
Why?
|
| Abnormal Karyotype | 2 | 2021 | 101 | 0.170 |
Why?
|
| Phosphorylation | 10 | 2017 | 4942 | 0.170 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 2 | 2010 | 37 | 0.170 |
Why?
|
| Wnt-5a Protein | 1 | 2019 | 46 | 0.170 |
Why?
|
| T-Lymphocytes | 6 | 2019 | 3949 | 0.170 |
Why?
|
| Cohort Studies | 10 | 2024 | 9470 | 0.160 |
Why?
|
| Proteolysis | 1 | 2021 | 380 | 0.160 |
Why?
|
| Transplantation, Homologous | 7 | 2018 | 3046 | 0.160 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2018 | 28 | 0.160 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2023 | 1097 | 0.160 |
Why?
|
| Bone Marrow Cells | 4 | 2011 | 968 | 0.160 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2018 | 45 | 0.160 |
Why?
|
| Administration, Oral | 6 | 2019 | 1608 | 0.160 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 558 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2023 | 1655 | 0.160 |
Why?
|
| Viral Load | 2 | 2018 | 485 | 0.160 |
Why?
|
| Graft vs Host Disease | 5 | 2022 | 2810 | 0.160 |
Why?
|
| Erythroid Precursor Cells | 1 | 1998 | 70 | 0.150 |
Why?
|
| Hepatitis B | 1 | 2021 | 275 | 0.150 |
Why?
|
| Thrombopoietin | 1 | 1998 | 102 | 0.150 |
Why?
|
| Integrin alpha4beta1 | 1 | 2018 | 46 | 0.150 |
Why?
|
| Methotrexate | 6 | 2022 | 1025 | 0.150 |
Why?
|
| Caspases | 4 | 2008 | 679 | 0.150 |
Why?
|
| Vomiting | 4 | 2015 | 361 | 0.150 |
Why?
|
| Lymphoma | 2 | 2003 | 1519 | 0.150 |
Why?
|
| Hyperbilirubinemia | 1 | 2018 | 78 | 0.150 |
Why?
|
| Morbidity | 1 | 2019 | 400 | 0.150 |
Why?
|
| B-Lymphocytes, Regulatory | 1 | 2017 | 23 | 0.150 |
Why?
|
| Thiazoles | 4 | 2023 | 723 | 0.150 |
Why?
|
| Vitamin B Complex | 1 | 2018 | 52 | 0.150 |
Why?
|
| Benzimidazoles | 2 | 2019 | 437 | 0.150 |
Why?
|
| Granulocytes | 1 | 1998 | 244 | 0.150 |
Why?
|
| Metaphase | 1 | 2017 | 124 | 0.150 |
Why?
|
| BK Virus | 1 | 2018 | 126 | 0.150 |
Why?
|
| Carnitine | 1 | 2018 | 89 | 0.150 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 191 | 0.150 |
Why?
|
| Anticoagulants | 1 | 2023 | 775 | 0.150 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 2 | 2017 | 114 | 0.140 |
Why?
|
| Maximum Tolerated Dose | 8 | 2017 | 1322 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2017 | 329 | 0.140 |
Why?
|
| Hepacivirus | 1 | 2020 | 423 | 0.140 |
Why?
|
| Models, Biological | 4 | 2017 | 3194 | 0.140 |
Why?
|
| Calreticulin | 1 | 2017 | 86 | 0.140 |
Why?
|
| Antagomirs | 1 | 2016 | 20 | 0.140 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2001 | 678 | 0.140 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 398 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2017 | 102 | 0.140 |
Why?
|
| Harringtonines | 2 | 2017 | 93 | 0.140 |
Why?
|
| Anemia, Aplastic | 1 | 2018 | 232 | 0.140 |
Why?
|
| Immunoglobulin D | 1 | 2016 | 17 | 0.140 |
Why?
|
| Incidence | 8 | 2023 | 5824 | 0.140 |
Why?
|
| Casein Kinase II | 1 | 2017 | 62 | 0.140 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 418 | 0.140 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2016 | 24 | 0.140 |
Why?
|
| Burkitt Lymphoma | 2 | 2017 | 350 | 0.140 |
Why?
|
| Interferon Type I | 2 | 1995 | 282 | 0.130 |
Why?
|
| Receptors, Notch | 1 | 2019 | 372 | 0.130 |
Why?
|
| Texas | 7 | 2019 | 6449 | 0.130 |
Why?
|
| Gene Expression Profiling | 4 | 2019 | 5149 | 0.130 |
Why?
|
| Neoplasms | 5 | 2018 | 15927 | 0.130 |
Why?
|
| Predictive Value of Tests | 9 | 2019 | 4960 | 0.130 |
Why?
|
| Interleukin-6 | 3 | 2017 | 1050 | 0.130 |
Why?
|
| Gene Deletion | 3 | 2013 | 1474 | 0.130 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2018 | 383 | 0.130 |
Why?
|
| Hepatitis B, Chronic | 1 | 2017 | 139 | 0.130 |
Why?
|
| Angiogenesis Inducing Agents | 2 | 2006 | 105 | 0.130 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 550 | 0.130 |
Why?
|
| Patient Safety | 2 | 2018 | 613 | 0.130 |
Why?
|
| Induction Chemotherapy | 5 | 2019 | 670 | 0.130 |
Why?
|
| Cells, Cultured | 8 | 2019 | 5694 | 0.130 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 1823 | 0.130 |
Why?
|
| Hepatitis B virus | 1 | 2017 | 225 | 0.130 |
Why?
|
| Macrophages | 2 | 2020 | 1350 | 0.130 |
Why?
|
| Immune Tolerance | 2 | 2017 | 427 | 0.120 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2015 | 76 | 0.120 |
Why?
|
| Cell Division | 5 | 2006 | 2657 | 0.120 |
Why?
|
| Lipoprotein Lipase | 1 | 2015 | 67 | 0.120 |
Why?
|
| Imidazoles | 2 | 2015 | 1065 | 0.120 |
Why?
|
| Ondansetron | 1 | 2015 | 39 | 0.120 |
Why?
|
| Erythema | 1 | 2014 | 48 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 4372 | 0.120 |
Why?
|
| Hepatitis C | 1 | 2020 | 549 | 0.120 |
Why?
|
| Leukocyte Count | 6 | 2017 | 735 | 0.120 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2017 | 1470 | 0.120 |
Why?
|
| Monokines | 1 | 1994 | 15 | 0.120 |
Why?
|
| Lipid Metabolism | 1 | 2018 | 476 | 0.120 |
Why?
|
| Antiviral Agents | 3 | 2021 | 1253 | 0.120 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 26 | 0.120 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 680 | 0.120 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 880 | 0.120 |
Why?
|
| Viral Matrix Proteins | 1 | 2015 | 181 | 0.120 |
Why?
|
| Cell Death | 1 | 2017 | 685 | 0.120 |
Why?
|
| Integrin alpha4 | 1 | 2014 | 26 | 0.120 |
Why?
|
| Leukapheresis | 1 | 2014 | 166 | 0.120 |
Why?
|
| Leukocytosis | 1 | 2014 | 123 | 0.110 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 681 | 0.110 |
Why?
|
| Transplantation Conditioning | 3 | 2022 | 2374 | 0.110 |
Why?
|
| Aminoglycosides | 5 | 2017 | 233 | 0.110 |
Why?
|
| Alleles | 2 | 2011 | 2600 | 0.110 |
Why?
|
| Infection Control | 1 | 2016 | 278 | 0.110 |
Why?
|
| Up-Regulation | 4 | 2016 | 2422 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2012 | 4644 | 0.110 |
Why?
|
| North Carolina | 1 | 2013 | 82 | 0.110 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 1099 | 0.110 |
Why?
|
| Disease Management | 2 | 2016 | 1090 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2017 | 1525 | 0.110 |
Why?
|
| Parvovirus B19, Human | 1 | 2013 | 40 | 0.110 |
Why?
|
| Morpholines | 1 | 2015 | 296 | 0.110 |
Why?
|
| Parvoviridae Infections | 1 | 2013 | 46 | 0.110 |
Why?
|
| NF-kappa B | 2 | 2017 | 1563 | 0.110 |
Why?
|
| Fatal Outcome | 1 | 2015 | 822 | 0.110 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2007 | 617 | 0.110 |
Why?
|
| Karyotype | 3 | 2019 | 237 | 0.110 |
Why?
|
| Endothelial Cells | 3 | 2022 | 1038 | 0.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2017 | 625 | 0.100 |
Why?
|
| Recombinant Proteins | 8 | 2008 | 3028 | 0.100 |
Why?
|
| Blast Crisis | 4 | 2023 | 588 | 0.100 |
Why?
|
| Cyclohexylamines | 1 | 2012 | 17 | 0.100 |
Why?
|
| Microvessels | 1 | 2013 | 145 | 0.100 |
Why?
|
| Glycoproteins | 5 | 2009 | 779 | 0.100 |
Why?
|
| Myeloproliferative Disorders | 2 | 2012 | 882 | 0.100 |
Why?
|
| Pyridazines | 1 | 2015 | 324 | 0.100 |
Why?
|
| Drug Therapy, Combination | 5 | 2018 | 2345 | 0.100 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2013 | 201 | 0.100 |
Why?
|
| Liposomes | 3 | 2009 | 704 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 592 | 0.100 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2006 | 361 | 0.100 |
Why?
|
| Cell Nucleus | 3 | 2017 | 1712 | 0.100 |
Why?
|
| Epigenesis, Genetic | 2 | 2017 | 1441 | 0.100 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2011 | 50 | 0.100 |
Why?
|
| Nomograms | 3 | 2011 | 312 | 0.100 |
Why?
|
| Mass Screening | 1 | 2020 | 1552 | 0.100 |
Why?
|
| Acute Kidney Injury | 2 | 2016 | 761 | 0.100 |
Why?
|
| Receptors, Cell Surface | 2 | 2011 | 904 | 0.100 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2011 | 56 | 0.090 |
Why?
|
| Lymphocyte Subsets | 1 | 2011 | 138 | 0.090 |
Why?
|
| Fatigue | 4 | 2023 | 1275 | 0.090 |
Why?
|
| Lung Neoplasms | 3 | 2020 | 12033 | 0.090 |
Why?
|
| Poly Adenosine Diphosphate Ribose | 1 | 2010 | 9 | 0.090 |
Why?
|
| Immunoglobulin G | 3 | 2017 | 1129 | 0.090 |
Why?
|
| Transcriptome | 1 | 2019 | 1963 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 4 | 2018 | 770 | 0.090 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 625 | 0.090 |
Why?
|
| Nitriles | 3 | 2019 | 939 | 0.090 |
Why?
|
| B7-H1 Antigen | 1 | 2017 | 1089 | 0.090 |
Why?
|
| Central Nervous System | 1 | 2013 | 451 | 0.090 |
Why?
|
| Transcription Factor RelA | 1 | 2011 | 184 | 0.090 |
Why?
|
| Pleural Effusion | 1 | 2012 | 228 | 0.090 |
Why?
|
| Liver Diseases | 1 | 2015 | 602 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2015 | 694 | 0.090 |
Why?
|
| Genes, Neoplasm | 1 | 2011 | 314 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2016 | 1281 | 0.090 |
Why?
|
| Trans-Activators | 2 | 2007 | 1624 | 0.090 |
Why?
|
| Phenotype | 2 | 2020 | 6509 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2399 | 0.090 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 284 | 0.090 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2011 | 247 | 0.090 |
Why?
|
| Platelet Count | 2 | 2019 | 492 | 0.080 |
Why?
|
| Vaccination | 1 | 2016 | 1166 | 0.080 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2010 | 162 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2005 | 5681 | 0.080 |
Why?
|
| Boronic Acids | 1 | 2011 | 354 | 0.080 |
Why?
|
| Time | 2 | 2020 | 183 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2011 | 2617 | 0.080 |
Why?
|
| Fever | 1 | 2012 | 521 | 0.080 |
Why?
|
| Hematopoiesis | 1 | 1993 | 602 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 1340 | 0.080 |
Why?
|
| Syndrome | 3 | 2021 | 1407 | 0.080 |
Why?
|
| Mycoses | 1 | 2013 | 393 | 0.080 |
Why?
|
| Chromosome Disorders | 1 | 2011 | 423 | 0.080 |
Why?
|
| Cell Line, Tumor | 7 | 2017 | 14849 | 0.080 |
Why?
|
| Lymphocyte Activation | 1 | 2014 | 1723 | 0.080 |
Why?
|
| Cell Survival | 4 | 2019 | 3063 | 0.080 |
Why?
|
| Erythrocyte Transfusion | 1 | 2011 | 206 | 0.080 |
Why?
|
| Pentostatin | 3 | 2019 | 121 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2011 | 593 | 0.080 |
Why?
|
| Hydroxamic Acids | 2 | 2010 | 454 | 0.080 |
Why?
|
| Genetic Therapy | 1 | 2016 | 1716 | 0.080 |
Why?
|
| Cell Cycle | 3 | 2007 | 2137 | 0.080 |
Why?
|
| Mycobacterium marinum | 1 | 2008 | 5 | 0.080 |
Why?
|
| Mitoxantrone | 2 | 2009 | 227 | 0.080 |
Why?
|
| Alkaline Phosphatase | 1 | 2009 | 214 | 0.080 |
Why?
|
| Chymotrypsin | 1 | 2008 | 37 | 0.080 |
Why?
|
| Neutrophils | 1 | 2013 | 873 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2008 | 183 | 0.080 |
Why?
|
| Medicare | 2 | 2024 | 926 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2011 | 2090 | 0.080 |
Why?
|
| STAT5 Transcription Factor | 2 | 2006 | 226 | 0.080 |
Why?
|
| Propensity Score | 2 | 2022 | 772 | 0.080 |
Why?
|
| Trypsin | 1 | 2008 | 156 | 0.080 |
Why?
|
| Syndecan-1 | 1 | 2008 | 52 | 0.080 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2008 | 42 | 0.070 |
Why?
|
| Treatment Failure | 5 | 2015 | 1430 | 0.070 |
Why?
|
| Yttrium Radioisotopes | 1 | 2009 | 210 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 1 | 2011 | 695 | 0.070 |
Why?
|
| Age Factors | 8 | 2017 | 5457 | 0.070 |
Why?
|
| Cell Adhesion | 3 | 2018 | 1028 | 0.070 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2008 | 632 | 0.070 |
Why?
|
| Microfluidics | 1 | 2007 | 32 | 0.070 |
Why?
|
| DNA-Binding Proteins | 3 | 2011 | 5002 | 0.070 |
Why?
|
| Animals | 8 | 2021 | 61956 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2020 | 690 | 0.070 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2008 | 86 | 0.070 |
Why?
|
| Smith-Magenis Syndrome | 3 | 2014 | 126 | 0.070 |
Why?
|
| Fungemia | 2 | 2006 | 119 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2011 | 1580 | 0.070 |
Why?
|
| Serum Albumin | 1 | 2007 | 246 | 0.070 |
Why?
|
| Meninges | 1 | 2007 | 50 | 0.070 |
Why?
|
| Lymphatic Diseases | 1 | 2007 | 127 | 0.070 |
Why?
|
| Transcriptional Activation | 1 | 2011 | 1111 | 0.070 |
Why?
|
| Hypereosinophilic Syndrome | 2 | 2007 | 86 | 0.070 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2018 | 1903 | 0.070 |
Why?
|
| Pneumococcal Vaccines | 1 | 2008 | 183 | 0.070 |
Why?
|
| Leukemic Infiltration | 1 | 2007 | 73 | 0.070 |
Why?
|
| Kidney | 1 | 2015 | 2121 | 0.070 |
Why?
|
| RNA, Messenger | 6 | 2013 | 6390 | 0.070 |
Why?
|
| Immunocompromised Host | 2 | 2018 | 719 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 4 | 2016 | 3216 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2024 | 2057 | 0.070 |
Why?
|
| Lymphoma, T-Cell | 1 | 2009 | 366 | 0.070 |
Why?
|
| CD52 Antigen | 4 | 2009 | 47 | 0.070 |
Why?
|
| Biopsy | 1 | 2014 | 3484 | 0.070 |
Why?
|
| Thiosemicarbazones | 1 | 2006 | 24 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2007 | 895 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 1 | 1994 | 1456 | 0.070 |
Why?
|
| Cytomegalovirus Infections | 2 | 2007 | 495 | 0.070 |
Why?
|
| Matrix Metalloproteinases | 1 | 2006 | 138 | 0.070 |
Why?
|
| Leukemia, Lymphoid | 1 | 2006 | 289 | 0.070 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2014 | 750 | 0.060 |
Why?
|
| PPAR gamma | 1 | 2006 | 225 | 0.060 |
Why?
|
| Genes, T-Cell Receptor | 1 | 2005 | 11 | 0.060 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 513 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2023 | 1542 | 0.060 |
Why?
|
| Interleukin-11 | 1 | 2005 | 38 | 0.060 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2005 | 44 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2008 | 593 | 0.060 |
Why?
|
| Gene Expression | 1 | 2013 | 3640 | 0.060 |
Why?
|
| Acrylamides | 1 | 2005 | 68 | 0.060 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2007 | 381 | 0.060 |
Why?
|
| Deuterium | 1 | 2024 | 117 | 0.060 |
Why?
|
| Milk Proteins | 1 | 2005 | 127 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 483 | 0.060 |
Why?
|
| Risk | 3 | 2020 | 1939 | 0.060 |
Why?
|
| Genome, Human | 1 | 2012 | 1888 | 0.060 |
Why?
|
| Membrane Glycoproteins | 2 | 2015 | 1094 | 0.060 |
Why?
|
| DNA, Neoplasm | 1 | 2010 | 1958 | 0.060 |
Why?
|
| Cell Movement | 1 | 2012 | 2472 | 0.060 |
Why?
|
| Interleukin-1 | 3 | 1994 | 475 | 0.060 |
Why?
|
| Blood Platelets | 2 | 2019 | 677 | 0.060 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2004 | 197 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2014 | 4831 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2005 | 311 | 0.060 |
Why?
|
| Benzodiazepines | 1 | 2005 | 167 | 0.060 |
Why?
|
| Mastocytosis, Systemic | 1 | 2004 | 119 | 0.060 |
Why?
|
| Dioxolanes | 1 | 2003 | 51 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 2015 | 149 | 0.050 |
Why?
|
| Chickenpox | 1 | 2003 | 34 | 0.050 |
Why?
|
| Herpesvirus 3, Human | 1 | 2003 | 45 | 0.050 |
Why?
|
| NAD+ Nucleosidase | 1 | 2002 | 17 | 0.050 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2002 | 33 | 0.050 |
Why?
|
| Nuclear Proteins | 2 | 2011 | 3438 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 1903 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 4821 | 0.050 |
Why?
|
| Water | 1 | 2024 | 386 | 0.050 |
Why?
|
| Herpes Zoster | 1 | 2003 | 53 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2024 | 236 | 0.050 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2016 | 507 | 0.050 |
Why?
|
| Amphotericin B | 1 | 2004 | 298 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 7655 | 0.050 |
Why?
|
| Sarcoma, Myeloid | 1 | 2003 | 93 | 0.050 |
Why?
|
| Serine | 2 | 2017 | 391 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2004 | 361 | 0.050 |
Why?
|
| Drug Evaluation | 2 | 2020 | 432 | 0.050 |
Why?
|
| Antigens, CD34 | 2 | 1994 | 640 | 0.050 |
Why?
|
| Cytosine | 1 | 2003 | 155 | 0.050 |
Why?
|
| United States | 3 | 2024 | 15861 | 0.050 |
Why?
|
| Receptors, CXCR5 | 1 | 2022 | 29 | 0.050 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2006 | 460 | 0.050 |
Why?
|
| Antibodies, Anti-Idiotypic | 2 | 2014 | 101 | 0.050 |
Why?
|
| Sirolimus | 1 | 2006 | 831 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2019 | 1356 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 3339 | 0.050 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2005 | 506 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2002 | 247 | 0.050 |
Why?
|
| Kinetics | 1 | 2024 | 2220 | 0.050 |
Why?
|
| Single-Blind Method | 2 | 2018 | 413 | 0.050 |
Why?
|
| Case-Control Studies | 4 | 2015 | 6224 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2017 | 1199 | 0.050 |
Why?
|
| Chronic Disease | 4 | 2015 | 1824 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 2 | 2013 | 5231 | 0.050 |
Why?
|
| Patient Selection | 3 | 2018 | 2025 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 3917 | 0.050 |
Why?
|
| Gene Rearrangement | 1 | 2005 | 813 | 0.050 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2022 | 219 | 0.050 |
Why?
|
| Benzothiazoles | 1 | 2021 | 103 | 0.050 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2021 | 89 | 0.050 |
Why?
|
| HeLa Cells | 2 | 2017 | 1685 | 0.050 |
Why?
|
| Prevalence | 2 | 2020 | 3404 | 0.050 |
Why?
|
| Stem Cell Factor | 2 | 1998 | 84 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2004 | 605 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2002 | 482 | 0.040 |
Why?
|
| Guanine | 1 | 2021 | 157 | 0.040 |
Why?
|
| Cell Communication | 2 | 2011 | 512 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2022 | 628 | 0.040 |
Why?
|
| Proteomics | 2 | 2022 | 1427 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2021 | 239 | 0.040 |
Why?
|
| Protein Binding | 2 | 2019 | 3485 | 0.040 |
Why?
|
| Child | 7 | 2019 | 30559 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 4895 | 0.040 |
Why?
|
| Algorithms | 1 | 2011 | 3891 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 964 | 0.040 |
Why?
|
| Germany | 1 | 2019 | 123 | 0.040 |
Why?
|
| Lymph Nodes | 3 | 2018 | 3077 | 0.040 |
Why?
|
| Allografts | 1 | 2021 | 686 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 5866 | 0.040 |
Why?
|
| JC Virus | 1 | 2018 | 48 | 0.040 |
Why?
|
| Infusions, Parenteral | 1 | 2018 | 197 | 0.040 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2018 | 31 | 0.040 |
Why?
|
| Interleukin-3 | 1 | 1998 | 106 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2017 | 6177 | 0.040 |
Why?
|
| Injections, Subcutaneous | 2 | 2010 | 342 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 2009 | 254 | 0.040 |
Why?
|
| Receptor, Notch1 | 1 | 2019 | 217 | 0.040 |
Why?
|
| Phenylurea Compounds | 1 | 2021 | 600 | 0.040 |
Why?
|
| Genomics | 2 | 2023 | 2835 | 0.040 |
Why?
|
| DNA Methylation | 3 | 2019 | 2765 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2014 | 2311 | 0.040 |
Why?
|
| Acetylation | 2 | 2010 | 515 | 0.040 |
Why?
|
| Megakaryocytes | 1 | 1998 | 129 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2011 | 266 | 0.040 |
Why?
|
| Deuterium Oxide | 1 | 2017 | 23 | 0.040 |
Why?
|
| Deprescriptions | 1 | 2017 | 25 | 0.040 |
Why?
|
| Tumor Stem Cell Assay | 2 | 1994 | 230 | 0.030 |
Why?
|
| Bilirubin | 1 | 2018 | 226 | 0.030 |
Why?
|
| Pedigree | 1 | 2021 | 2042 | 0.030 |
Why?
|
| RNA, Small Interfering | 2 | 2014 | 2196 | 0.030 |
Why?
|
| Cellular Microenvironment | 1 | 2016 | 36 | 0.030 |
Why?
|
| Herpesvirus 8, Human | 1 | 2017 | 107 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 260 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2016 | 126 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2017 | 319 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 896 | 0.030 |
Why?
|
| K562 Cells | 1 | 2017 | 344 | 0.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2019 | 460 | 0.030 |
Why?
|
| Quinazolinones | 1 | 2016 | 52 | 0.030 |
Why?
|
| Liver Failure | 1 | 2017 | 141 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2016 | 201 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2017 | 497 | 0.030 |
Why?
|
| Medical Records | 1 | 2017 | 442 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 749 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2015 | 185 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 2650 | 0.030 |
Why?
|
| Age Distribution | 1 | 2017 | 727 | 0.030 |
Why?
|
| Glucocorticoids | 2 | 2009 | 617 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 199 | 0.030 |
Why?
|
| Blood Proteins | 1 | 2016 | 299 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2017 | 1049 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2016 | 273 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 497 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2016 | 255 | 0.030 |
Why?
|
| Etoposide | 1 | 2017 | 907 | 0.030 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 1994 | 72 | 0.030 |
Why?
|
| Adenosine Monophosphate | 1 | 1994 | 76 | 0.030 |
Why?
|
| Purines | 1 | 2016 | 271 | 0.030 |
Why?
|
| Thioguanine | 1 | 2014 | 69 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 1826 | 0.030 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 1994 | 36 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2016 | 293 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 722 | 0.030 |
Why?
|
| Mercaptopurine | 1 | 2014 | 130 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2015 | 353 | 0.030 |
Why?
|
| Cyclosporine | 2 | 2006 | 292 | 0.030 |
Why?
|
| Receptors, Granulocyte Colony-Stimulating Factor | 1 | 1993 | 33 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2008 | 1312 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 827 | 0.030 |
Why?
|
| Mice | 3 | 2021 | 35600 | 0.030 |
Why?
|
| Tumor Necrosis Factor Decoy Receptors | 1 | 1993 | 4 | 0.030 |
Why?
|
| Lymphotoxin-alpha | 1 | 1993 | 26 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2017 | 878 | 0.030 |
Why?
|
| Creatinine | 1 | 2015 | 529 | 0.030 |
Why?
|
| Waldenstrom Macroglobulinemia | 2 | 2014 | 285 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 907 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 1993 | 73 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 533 | 0.030 |
Why?
|
| Diarrhea | 2 | 2007 | 716 | 0.030 |
Why?
|
| Drug Resistance | 2 | 2011 | 610 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 2357 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 2067 | 0.030 |
Why?
|
| Optic Disk | 1 | 2013 | 54 | 0.030 |
Why?
|
| Oncogenes | 1 | 1996 | 699 | 0.030 |
Why?
|
| CHO Cells | 1 | 1993 | 320 | 0.030 |
Why?
|
| Tyrosine | 1 | 2014 | 508 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 1993 | 207 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2019 | 17061 | 0.030 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family Member 1 | 1 | 2011 | 10 | 0.030 |
Why?
|
| Syk Kinase | 1 | 2012 | 65 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 1388 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 2184 | 0.020 |
Why?
|
| Sialoglycoproteins | 1 | 1992 | 151 | 0.020 |
Why?
|
| Karyotyping | 2 | 2004 | 1063 | 0.020 |
Why?
|
| Cricetinae | 1 | 1993 | 769 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2016 | 1461 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2011 | 172 | 0.020 |
Why?
|
| Cause of Death | 1 | 2015 | 789 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2012 | 136 | 0.020 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2011 | 40 | 0.020 |
Why?
|
| Basophils | 1 | 2011 | 45 | 0.020 |
Why?
|
| Histones | 2 | 2010 | 1513 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 16215 | 0.020 |
Why?
|
| Interferon-beta | 1 | 1991 | 109 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 2013 | 271 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2018 | 1710 | 0.020 |
Why?
|
| Myeloablative Agonists | 1 | 2013 | 388 | 0.020 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2014 | 331 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 4130 | 0.020 |
Why?
|
| Clone Cells | 1 | 1992 | 591 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2019 | 8699 | 0.020 |
Why?
|
| Allopurinol | 1 | 2011 | 85 | 0.020 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2011 | 170 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2014 | 967 | 0.020 |
Why?
|
| Receptors, Interleukin-1 | 2 | 2005 | 97 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 1992 | 313 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2011 | 316 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 206 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 4492 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 5315 | 0.020 |
Why?
|
| Proteasome Inhibitors | 1 | 2011 | 235 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 742 | 0.020 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2010 | 117 | 0.020 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2010 | 125 | 0.020 |
Why?
|
| Transfection | 1 | 2015 | 3117 | 0.020 |
Why?
|
| Bortezomib | 1 | 2011 | 549 | 0.020 |
Why?
|
| Lentivirus | 1 | 2010 | 164 | 0.020 |
Why?
|
| Cisplatin | 1 | 2016 | 2497 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 4048 | 0.020 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2009 | 154 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2010 | 318 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2009 | 241 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 2255 | 0.020 |
Why?
|
| Radioimmunotherapy | 1 | 2009 | 128 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 2008 | 72 | 0.020 |
Why?
|
| Immunotherapy, Active | 1 | 2008 | 49 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2010 | 537 | 0.020 |
Why?
|
| Infant | 2 | 2019 | 13999 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2014 | 1033 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2012 | 825 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2013 | 1275 | 0.020 |
Why?
|
| Solubility | 1 | 2008 | 247 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2011 | 611 | 0.020 |
Why?
|
| Cell Separation | 1 | 2009 | 609 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 2007 | 123 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2011 | 889 | 0.020 |
Why?
|
| Polyradiculopathy | 1 | 2007 | 13 | 0.020 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 751 | 0.020 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2006 | 18 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 2471 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2006 | 79 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2012 | 5776 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2012 | 1192 | 0.020 |
Why?
|
| Injections, Spinal | 1 | 2007 | 273 | 0.020 |
Why?
|
| Spiro Compounds | 1 | 2006 | 59 | 0.020 |
Why?
|
| Meningitis | 1 | 2007 | 126 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2006 | 135 | 0.020 |
Why?
|
| Papilledema | 1 | 2007 | 87 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 3584 | 0.020 |
Why?
|
| CD146 Antigen | 1 | 2005 | 56 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 1568 | 0.020 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2005 | 53 | 0.020 |
Why?
|
| Base Pair Mismatch | 1 | 2005 | 82 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2007 | 520 | 0.020 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2005 | 72 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2005 | 107 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 984 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2006 | 296 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2007 | 364 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2005 | 178 | 0.020 |
Why?
|
| Encephalitis | 1 | 2007 | 153 | 0.020 |
Why?
|
| Bone Marrow Diseases | 1 | 2006 | 186 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 168 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 4208 | 0.020 |
Why?
|
| Killer Cells, Natural | 2 | 2006 | 965 | 0.020 |
Why?
|
| Antibodies | 1 | 2008 | 809 | 0.020 |
Why?
|
| Tubulin | 1 | 2005 | 202 | 0.020 |
Why?
|
| Leukocyte Common Antigens | 1 | 2005 | 191 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 591 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2008 | 704 | 0.020 |
Why?
|
| Chromosome Inversion | 1 | 2005 | 197 | 0.020 |
Why?
|
| Caspase 10 | 1 | 2004 | 22 | 0.020 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2006 | 201 | 0.010 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 336 | 0.010 |
Why?
|
| Enzyme Precursors | 1 | 2004 | 71 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2007 | 1075 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2007 | 622 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1993 | 2098 | 0.010 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2005 | 123 | 0.010 |
Why?
|
| World Health Organization | 1 | 2006 | 327 | 0.010 |
Why?
|
| Genotype | 1 | 2012 | 4252 | 0.010 |
Why?
|
| Janus Kinase 1 | 1 | 2005 | 125 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 661 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2007 | 1075 | 0.010 |
Why?
|
| Constipation | 1 | 2005 | 187 | 0.010 |
Why?
|
| Microtubules | 1 | 2005 | 329 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 1109 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2004 | 242 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2006 | 633 | 0.010 |
Why?
|
| Everolimus | 1 | 2006 | 436 | 0.010 |
Why?
|
| DNA Primers | 1 | 2006 | 1496 | 0.010 |
Why?
|
| Sepsis | 1 | 2009 | 686 | 0.010 |
Why?
|
| Genes, abl | 1 | 2003 | 119 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2004 | 187 | 0.010 |
Why?
|
| Neopterin | 2 | 1994 | 14 | 0.010 |
Why?
|
| Cell Line | 1 | 2011 | 5338 | 0.010 |
Why?
|
| Therapies, Investigational | 1 | 2003 | 60 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2007 | 1163 | 0.010 |
Why?
|
| Survival | 1 | 2003 | 183 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 714 | 0.010 |
Why?
|
| Cancer Vaccines | 1 | 2008 | 754 | 0.010 |
Why?
|
| Drugs, Investigational | 1 | 2003 | 130 | 0.010 |
Why?
|
| Skin | 1 | 2008 | 1271 | 0.010 |
Why?
|
| Leukopenia | 1 | 2003 | 152 | 0.010 |
Why?
|
| Quality of Life | 1 | 2017 | 4761 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2004 | 729 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2004 | 675 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2004 | 231 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2006 | 902 | 0.010 |
Why?
|
| Splenomegaly | 1 | 2003 | 173 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 886 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 7895 | 0.010 |
Why?
|
| Eosinophils | 1 | 2003 | 166 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2005 | 1810 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 2006 | 1060 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 460 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2006 | 1138 | 0.010 |
Why?
|
| Seizures | 1 | 2007 | 1001 | 0.010 |
Why?
|
| Age of Onset | 1 | 2003 | 853 | 0.010 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2005 | 637 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2003 | 805 | 0.010 |
Why?
|
| Research Design | 1 | 2008 | 1569 | 0.010 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2005 | 797 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2004 | 809 | 0.010 |
Why?
|
| Bacteremia | 1 | 2006 | 721 | 0.010 |
Why?
|
| Pneumonia | 1 | 2006 | 796 | 0.010 |
Why?
|
| Skin Diseases | 1 | 2003 | 366 | 0.010 |
Why?
|
| Peptides | 1 | 2005 | 1504 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2006 | 1563 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 2315 | 0.010 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2003 | 481 | 0.010 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2008 | 1840 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 1990 | 2328 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2003 | 517 | 0.010 |
Why?
|
| Platelet Aggregation | 1 | 1978 | 182 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 1978 | 178 | 0.010 |
Why?
|
| Pacemaker, Artificial | 1 | 1980 | 206 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2006 | 2115 | 0.010 |
Why?
|
| DNA Repair | 1 | 2005 | 1909 | 0.010 |
Why?
|
| DNA | 1 | 2005 | 3050 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2003 | 2353 | 0.010 |
Why?
|
| Myxovirus Resistance Proteins | 1 | 1994 | 16 | 0.010 |
Why?
|
| Lipids | 1 | 1978 | 654 | 0.010 |
Why?
|
| Heart | 1 | 1980 | 1195 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 1994 | 341 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 1993 | 72 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1993 | 255 | 0.010 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 1992 | 39 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 1992 | 104 | 0.010 |
Why?
|
| Erythropoietin | 1 | 1993 | 224 | 0.010 |
Why?
|
| Culture Media | 1 | 1992 | 344 | 0.010 |
Why?
|
| Lymphocyte Depletion | 1 | 1992 | 316 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1994 | 1028 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1991 | 1179 | 0.000 |
Why?
|
| Phonocardiography | 1 | 1980 | 7 | 0.000 |
Why?
|
| Pulse | 1 | 1980 | 38 | 0.000 |
Why?
|
| Heart Block | 1 | 1980 | 45 | 0.000 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 1978 | 14 | 0.000 |
Why?
|
| Myocardial Contraction | 1 | 1980 | 301 | 0.000 |
Why?
|
| Lipoproteins, VLDL | 1 | 1978 | 67 | 0.000 |
Why?
|
| Lipoproteins, LDL | 1 | 1978 | 145 | 0.000 |
Why?
|
| Lipoproteins, HDL | 1 | 1978 | 127 | 0.000 |
Why?
|
| Hemodynamics | 1 | 1980 | 949 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1980 | 1154 | 0.000 |
Why?
|
| Diet | 1 | 1978 | 1477 | 0.000 |
Why?
|